Mn Services Vermogensbeheer B.V. Has $8.66 Million Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Mn Services Vermogensbeheer B.V. lowered its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.4% in the third quarter, HoldingsChannel reports. The firm owned 80,200 shares of the medical equipment provider’s stock after selling 2,000 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Zimmer Biomet were worth $8,658,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of ZBH. BLB&B Advisors LLC boosted its stake in shares of Zimmer Biomet by 2.1% during the 3rd quarter. BLB&B Advisors LLC now owns 4,900 shares of the medical equipment provider’s stock worth $529,000 after acquiring an additional 100 shares during the period. Financial Advocates Investment Management boosted its position in Zimmer Biomet by 3.5% during the third quarter. Financial Advocates Investment Management now owns 3,053 shares of the medical equipment provider’s stock worth $330,000 after purchasing an additional 103 shares during the period. PFG Advisors increased its holdings in shares of Zimmer Biomet by 5.5% in the first quarter. PFG Advisors now owns 2,004 shares of the medical equipment provider’s stock valued at $265,000 after purchasing an additional 105 shares during the last quarter. M&R Capital Management Inc. raised its position in shares of Zimmer Biomet by 14.1% in the third quarter. M&R Capital Management Inc. now owns 852 shares of the medical equipment provider’s stock valued at $92,000 after purchasing an additional 105 shares during the period. Finally, Mill Creek Capital Advisors LLC lifted its stake in shares of Zimmer Biomet by 5.1% during the 2nd quarter. Mill Creek Capital Advisors LLC now owns 2,195 shares of the medical equipment provider’s stock worth $238,000 after buying an additional 106 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analysts Set New Price Targets

ZBH has been the topic of a number of research reports. Evercore ISI decreased their price target on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Canaccord Genuity Group decreased their target price on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating on the stock in a research report on Tuesday, September 10th. TD Cowen reduced their price target on Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a research note on Friday, September 6th. Wells Fargo & Company increased their price objective on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Finally, BTIG Research reduced their target price on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a research report on Thursday, October 3rd. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $124.11.

Zimmer Biomet Trading Up 0.5 %

Shares of ZBH stock opened at $108.92 on Wednesday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $101.47 and a fifty-two week high of $133.90. The company has a market cap of $21.68 billion, a PE ratio of 20.71, a P/E/G ratio of 1.99 and a beta of 1.02. The stock’s fifty day moving average price is $106.72 and its two-hundred day moving average price is $110.58.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting the consensus estimate of $1.74. The business had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. Zimmer Biomet’s revenue was up 4.1% compared to the same quarter last year. During the same period last year, the firm posted $1.65 earnings per share. Equities analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.88%. The ex-dividend date of this dividend was Monday, September 30th. Zimmer Biomet’s payout ratio is 18.25%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.